Kerecis

NEWS
Coloplast has signed an agreement to acquire Kerecis, an innovative, fast-growing company in the biologics wound care segment, for up to USD 1.3 billion (around DKK 8.9 billion), of which USD 1.2 billion (around DKK 8.2 billion) is an upfront cash payment.
IN THE PRESS
Kerecis, the pioneer in the use of fish skin and fatty acids for tissue regeneration and protection, will unveil its latest scientific and clinical updates, including trial results, at the upcoming Symposium on Advanced Wound Care Spring.
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, announced the availability of Shield Standard, which combines a fish-skin graft and silicone backing for efficient treatment of acute and chronic wounds.
Kerecis announced the publication of a multi-disciplinary clinical consensus about the utilization of fish skin grafts on complex wounds.
Kerecis® Shield™, the new fish-skin wound-treatment product family for private doctors’ clinics, has been approved by multiple leading Medicare Administrative Contractors.
Kerecis®, the company pioneering the use of fish skin and fatty acids for tissue regeneration and protection, is donating its GraftGuide® fish-skin burn product for victims of the fires on Maui, Hawaii.
SAWC – Kerecis® announced MariGen® Shield, which integrates the company’s proven fish-skin graft with a silicone contact layer for treating chronic and complex wounds.
Kerecis announced that, over the past year, 63 million more Americans became eligible for insurance coverage for the company’s fish-skin treatments, an increase of more than 70%.
Kerecis, the company pioneering the use of fish skin and fatty acids for tissue regeneration and protection, announced the release of two new products for the burn market, GraftGuide Mano™ and GraftGuide Micro™.
Kerecis®, the company pioneering the use of fish skin and fatty acids in cellular therapy, tissue regeneration and protection, has received authorization from the FDA to market Kerecis Omega3 SurgiBind™.
The easy-to-use fish-skin graft fills a void as wound-treatment companies withdraw human-derived products per FDA guidance